Donald C. Arbitblit

Donald C. Arbitblit is a leader among plaintiffs’ attorneys in assessing the legal, medical, and scientific aspects of personal injury, mass torts, and environmental and toxic exposure litigation. Don has served on Plaintiffs’ Science/Expert Committees in several national cases and served on the Plaintiffs’ Steering Committee in the Actos bladder cancer injuries federal multidistrict litigation that settled in 2015 for $2.4 billion.Don was a member of the trial team that won the first Actos bellwether trial in April 2014, including a $9 billion punitive damage award. Don was also Chair of the Epidemiology/Causation Subcommittee of the federal Vioxx litigation from 2005-2010, and he was a member of the trial team that won a plaintiffs’ verdict in that litigation in 2006. Between 1998 and 2014, Don has served on science and expert witness committees in the Actos, Yaz, Fen-Phen Diet Drug, Rezulin, Baycol, Vioxx, and Sulzer hip implant cases.Since 2018, Don has served as a leader of the Plaintiffs’ Expert Witness Committee in the national Opioids Litigation MDL, working with experts in the fields of addiction medicine, psychiatry, pain management and epidemiology. Don was listed in the 2021 Lawdragon 500 Leading Plaintiff Consumer Lawyers guide, based on “submissions, journalistic research and editorial vetting from a board” of his peers.

Donald C. Arbitblit is a leader among plaintiffs’ attorneys in assessing the legal, medical, and scientific aspects of personal injury, mass torts, and environmental and toxic exposure litigation. Don has served on Plaintiffs’ Science/Expert Committees in several national cases and served on the Plaintiffs’ Steering Committee in the Actos bladder cancer injuries federal multidistrict litigation that settled in 2015 for $2.4 billion.Don was a member of the trial team that won the first Actos bellwether trial in April 2014, including a $9 billion punitive damage award. Don was also Chair of the Epidemiology/Causation Subcommittee of the federal Vioxx litigation from 2005-2010, and he was a member of the trial team that won a plaintiffs’ verdict in that litigation in 2006. Between 1998 and 2014, Don has served on science and expert witness committees in the Actos, Yaz, Fen-Phen Diet Drug, Rezulin, Baycol, Vioxx, and Sulzer hip implant cases.Since 2018, Don has served as a leader of the Plaintiffs’ Expert Witness Committee in the national Opioids Litigation MDL, working with experts in the fields of addiction medicine, psychiatry, pain management and epidemiology. Don was listed in the 2021 Lawdragon 500 Leading Plaintiff Consumer Lawyers guide, based on “submissions, journalistic research and editorial vetting from a board” of his peers.

Donald C. Arbitblit is a leader among plaintiffs’ attorneys in assessing the legal, medical, and scientific aspects of personal injury, mass torts, and environmental and toxic exposure litigation. Don has served on Plaintiffs’ Science/Expert Committees in several national cases and served on the Plaintiffs’ Steering Committee in the Actos bladder cancer injuries federal multidistrict litigation that settled in 2015 for $2.4 billion.

Don was a member of the trial team that won the first Actos bellwether trial in April 2014, including a $9 billion punitive damage award. Don was also Chair of the Epidemiology/Causation Subcommittee of the federal Vioxx litigation from 2005-2010, and he was a member of the trial team that won a plaintiffs’ verdict in that litigation in 2006. Between 1998 and 2014, Don has served on science and expert witness committees in the Actos, Yaz, Fen-Phen Diet Drug, Rezulin, Baycol, Vioxx, and Sulzer hip implant cases.

Since 2018, Don has served as a leader of the Plaintiffs’ Expert Witness Committee in the national Opioids Litigation MDL, working with experts in the fields of addiction medicine, psychiatry, pain management and epidemiology. Don was listed in the 2021 Lawdragon 500 Leading Plaintiff Consumer Lawyers guide, based on “submissions, journalistic research and editorial vetting from a board” of his peers.